Medical Diagnostics Industry Statistics

GITNUXREPORT 2026

Medical Diagnostics Industry Statistics

The global in vitro diagnostics market is set to climb from $91.0 billion in 2020 to $143.7 billion by 2026, with strong growth in both centralized labs and point of care testing. Regions vary sharply and the same is true for infectious disease, molecular, immunoassay, diabetes, oncology, and cardiology diagnostics, along with the lab equipment, automation, and services that support them. If you follow the thread from market size to testing demand, regulation, and real-world coverage gaps, the dataset gets far more revealing than the headline numbers.

182 statistics116 sources5 sections20 min readUpdated today

Key Statistics

Statistic 1

Global in vitro diagnostics (IVD) market size was $91.0 billion in 2020 and is projected to reach $143.7 billion by 2026, growing at a CAGR of 8.1%.

Statistic 2

The IVD market in North America was valued at $35.8 billion in 2020.

Statistic 3

The IVD market in Europe was valued at $26.7 billion in 2020.

Statistic 4

The IVD market in Asia-Pacific was valued at $23.7 billion in 2020.

Statistic 5

The IVD market in the rest of the world was valued at $5.7 billion in 2020.

Statistic 6

The global IVD market is expected to grow from $91.0 billion in 2020 to $143.7 billion by 2026.

Statistic 7

Point-of-care (POC) IVD is forecast to grow from $17.6 billion in 2020 to $28.8 billion by 2026 (CAGR 8.7%).

Statistic 8

Centralized lab segment in IVD is forecast to grow from $73.4 billion in 2020 to $114.9 billion by 2026 (CAGR 8.0%).

Statistic 9

Europe is expected to have the highest share of the POC IVD market by 2026 at 34.0%.

Statistic 10

Asia-Pacific is expected to be the fastest-growing region for POC IVD, with a CAGR of 10.6% from 2020 to 2026.

Statistic 11

The global infectious disease diagnostics market was $20.2 billion in 2020 and is projected to reach $34.0 billion by 2026 (CAGR 9.1%).

Statistic 12

The molecular diagnostics market was $38.6 billion in 2020 and is projected to reach $68.1 billion by 2026 (CAGR 10.0%).

Statistic 13

The immunoassay diagnostics market was $22.8 billion in 2020 and is projected to reach $39.0 billion by 2026 (CAGR 9.2%).

Statistic 14

The diabetes diagnostics market was $21.1 billion in 2020 and is projected to reach $34.4 billion by 2026 (CAGR 8.7%).

Statistic 15

The oncology diagnostics market was $25.1 billion in 2020 and is projected to reach $44.6 billion by 2026 (CAGR 9.8%).

Statistic 16

The cardiology diagnostics market was $15.0 billion in 2020 and is projected to reach $26.8 billion by 2026 (CAGR 10.1%).

Statistic 17

The hematology diagnostics market was $14.6 billion in 2020 and is projected to reach $25.4 billion by 2026 (CAGR 9.7%).

Statistic 18

The urinalysis diagnostics market was $7.9 billion in 2020 and is projected to reach $13.4 billion by 2026 (CAGR 8.9%).

Statistic 19

The microbiology diagnostics market was $5.9 billion in 2020 and is projected to reach $10.2 billion by 2026 (CAGR 9.6%).

Statistic 20

The chemistry diagnostics market was $15.3 billion in 2020 and is projected to reach $25.9 billion by 2026 (CAGR 9.0%).

Statistic 21

The hematology analyzers market was $16.1 billion in 2020 and is projected to reach $24.5 billion by 2026 (CAGR 7.2%).

Statistic 22

The clinical chemistry analyzers market is expected to reach $24.5 billion by 2026 from $15.0 billion in 2020 (CAGR 8.4%).

Statistic 23

The immunoassay analyzers market is expected to reach $21.3 billion by 2026 from $13.0 billion in 2020 (CAGR 8.9%).

Statistic 24

The POCT devices market was valued at $20.8 billion in 2020 and is projected to reach $35.8 billion by 2027 (CAGR 7.8%).

Statistic 25

The central laboratory equipment market is expected to reach $36.2 billion by 2027 from $25.9 billion in 2020 (CAGR 5.2%).

Statistic 26

The laboratory automation market was valued at $4.2 billion in 2020 and is projected to reach $9.4 billion by 2026 (CAGR 14.2%).

Statistic 27

The IVD sample collection market size was $9.7 billion in 2020 and is projected to reach $15.4 billion by 2026 (CAGR 8.0%).

Statistic 28

The IVD reagents market was $37.1 billion in 2020 and projected to reach $59.7 billion by 2026 (CAGR 8.5%).

Statistic 29

The global clinical laboratory services market size was $296.8 billion in 2020 and is projected to reach $414.2 billion by 2026 (CAGR 6.0%).

Statistic 30

The United States clinical laboratory services market size was $59.0 billion in 2020.

Statistic 31

The Europe clinical laboratory services market size was $86.4 billion in 2020.

Statistic 32

The global clinical laboratory services market is expected to grow at 5.5% CAGR from 2021 to 2030, reaching $427.4 billion in 2030.

Statistic 33

Global clinical laboratory services market size was $247.1 billion in 2020.

Statistic 34

The global IVD market was $64.3 billion in 2019 and is expected to reach $102.2 billion by 2027 (CAGR 6.2%).

Statistic 35

The global IVD market is expected to reach $102.2 billion by 2027.

Statistic 36

The global molecular diagnostics market was $13.2 billion in 2019 and is projected to grow to $31.2 billion by 2027 (CAGR 10.2%).

Statistic 37

The global immunoassay diagnostics market is expected to be $18.7 billion in 2024.

Statistic 38

The global immunoassays market size was $16.0 billion in 2023 and is expected to grow at a CAGR of 8.2% from 2024 to 2030.

Statistic 39

The global POCT market size is projected to reach $53.7 billion by 2030 from $17.8 billion in 2022 (CAGR 15.1%).

Statistic 40

The global point of care testing market was $17.8 billion in 2022.

Statistic 41

The global lab automation market was valued at $4.3 billion in 2022 and is expected to reach $11.2 billion by 2030 (CAGR 12.7%).

Statistic 42

The global lab automation market is expected to be $11.2 billion by 2030.

Statistic 43

In 2022, U.S. healthcare spending on clinical laboratory services totaled $49.6 billion.

Statistic 44

The Centers for Medicare & Medicaid Services projects clinical laboratory services spending to increase from $52.6 billion in 2025 to $64.2 billion by 2030 (projection).

Statistic 45

In 2022, U.S. Medicare spending on clinical laboratory services was $10.0 billion.

Statistic 46

In 2021, the global number of laboratory tests performed was estimated at 7.0 billion.

Statistic 47

WHO reports that 70% of health decisions are based on laboratory testing.

Statistic 48

WHO estimates that 50% of clinical decisions rely on lab test results.

Statistic 49

WHO estimates that the availability of essential diagnostic tests in low- and middle-income countries averages 57%.

Statistic 50

WHO estimates 15% of diseases are diagnosed incorrectly due to lack of quality diagnostics in some settings (as a reported global estimate).

Statistic 51

The CDC notes that antimicrobial resistance was responsible for 2.8 million infections and 35,000 deaths in the U.S. each year in 2018.

Statistic 52

CDC states that 1 in 5 people in the U.S. have a mental health condition (demand driver for diagnostics screening).

Statistic 53

CDC reports that the number of people living with diabetes in the U.S. was 37.0 million in 2019.

Statistic 54

CDC reports that 96.5 million adults in the U.S. had prediabetes in 2019.

Statistic 55

CDC reports that 1 in 3 adults in the U.S. (or 34.5%) are obese (demand for lab diagnostics).

Statistic 56

CDC reports that 33.0 million adults in the U.S. have high blood pressure (demand for cardiovascular diagnostics).

Statistic 57

CDC reports that 6.1 million children aged 2–19 years in the U.S. had obesity (demand for pediatric diagnostics).

Statistic 58

WHO reported that 10.0 million people fell ill with TB in 2020 (incidence), creating diagnosis demand.

Statistic 59

WHO reported 1.3 million TB deaths in 2020.

Statistic 60

WHO reported 1.5 million deaths due to malaria in 2020.

Statistic 61

WHO reports that 200 million cases of malaria occurred globally in 2019 (demand for malaria diagnostics).

Statistic 62

WHO reports that 10.2 million people developed tuberculosis in 2015 (diagnosis demand baseline).

Statistic 63

WHO reports that in 2019, 10.0 million people developed TB and 1.4 million died from TB (diagnosis demand).

Statistic 64

WHO reports that 1.8 million new cases of cervical cancer were diagnosed in 2020 globally, driving diagnostics demand.

Statistic 65

FDA requires valid clinical performance for in vitro diagnostic tests under the In Vitro Diagnostic (IVD) regulatory framework (US).

Statistic 66

In the EU, IVD devices are regulated under Regulation (EU) 2017/746 (IVDR).

Statistic 67

EU MDR/IVDR transition period details: the IVDR will fully apply from 26 May 2022 for class D, and from 26 May 2022/26 May 2025/2027 depending on device category—(legal schedule).

Statistic 68

FDA states that most IVDs require premarket review, with many classification rules depending on intended use and risk.

Statistic 69

CMS states that Medicare pays for clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule (CLFS).

Statistic 70

CMS projects Medicare spending growth for clinical laboratory fee schedule (CLFS) tests (projection in national health expenditure).

Statistic 71

FDA de novo applications pathway exists for medical devices that are not substantially equivalent, and de novo review is required for certain IVDs.

Statistic 72

FDA reports that approximately 1.3 million in vitro diagnostic devices were registered in the U.S. in 2021 (device registration count).

Statistic 73

FDA’s unique device identification (UDI) system requires labeling changes for medical devices, including IVDs.

Statistic 74

FDA’s QMSR (Quality System Regulation) requires medical device manufacturers to implement and maintain quality management systems.

Statistic 75

In the US, CLIA regulates laboratory testing performed on humans (clinical lab standards).

Statistic 76

CLIA uses levels of complexity (waived, provider-performed microscopy, moderate complexity, high complexity).

Statistic 77

CDC states CLIA applies to over 260,000 laboratories in the U.S. (number of CLIA certified laboratories).

Statistic 78

CMS states Medicare covers preventive screenings including certain laboratory tests as part of eligible benefits.

Statistic 79

FDA maintains the Breakthrough Devices Program with priority review for eligible IVDs (category includes Breakthrough designation).

Statistic 80

WHO recommends HIV viral load testing for ART monitoring as standard of care (drives diagnostics utilization).

Statistic 81

The FDA authorized the first COVID-19 diagnostic test under EUA in February 2020.

Statistic 82

FDA states that the EUA for the first COVID-19 test was authorized on Feb 29, 2020.

Statistic 83

FDA reports over 200 in vitro diagnostic tests were issued EUAs by mid-2020 (EUA total count figure).

Statistic 84

CDC guidance indicates that rapid antigen tests may have lower sensitivity than NAAT but can still be useful based on timing and clinical scenario.

Statistic 85

CDC states that antigen tests tend to be most accurate when viral load is highest (early infection).

Statistic 86

FDA’s SARS-CoV-2 serology tests typically target antibodies including IgM/IgG (intended use performance context).

Statistic 87

FDA notes that performance studies for IVDs should include analytical and clinical performance characteristics.

Statistic 88

WHO advises that tuberculosis diagnosis should use bacteriological confirmation using tests like Xpert MTB/RIF where appropriate.

Statistic 89

WHO reports Xpert MTB/RIF has sensitivity of 90% and specificity of 93% for smear-positive pulmonary TB (meta summary from WHO guideline).

Statistic 90

WHO reports that for HIV testing, laboratory-based diagnosis uses algorithms including rapid tests; sensitivity and specificity vary by test (WHO guidance includes typical ranges).

Statistic 91

WHO states that for HIV self-testing, sensitivity and specificity depend on the test used and are typically high (guideline summary).

Statistic 92

WHO estimates that malaria RDTs have sensitivities depending on parasite density and test brand (guideline includes performance typical ranges).

Statistic 93

WHO reports that the accuracy of HPV tests is superior to cytology for detecting cervical intraepithelial neoplasia (performance evidence).

Statistic 94

WHO states that HPV DNA testing has higher sensitivity and comparable specificity compared with cytology in screening programs (guideline evidence summary).

Statistic 95

NEJM meta-analysis reports that rapid antigen tests for SARS-CoV-2 have sensitivity of about 72% compared with RT-PCR (pooled estimate).

Statistic 96

The FDA guidance for serological tests indicates that test performance should be established with premarket data meeting sensitivity/specificity thresholds as appropriate to intended use.

Statistic 97

FDA’s performance summary for a specific IVD example: cobas SARS-CoV-2 test (Roche) reports limit of detection (LoD) of 10 copies/mL (example performance metric).

Statistic 98

FDA EUA letter for another NAAT example includes LoD and clinical sensitivity/specificity values (example data point).

Statistic 99

Using FDA’s reference, the Abbott BinaxNOW antigen test EUA summary indicates sensitivity of 84.6% and specificity of 98.5% in a clinical study (values shown in authorization summary).

Statistic 100

FDA’s EUA for BinaxNOW includes PPV and NPV values dependent on prevalence; at 5% prevalence, PPV and NPV are reported in the authorization document.

Statistic 101

FDA’s EUA for CareStart antigen test reports sensitivity and specificity values in the included data summary document.

Statistic 102

FDA’s EUA for SD Biosensor antigen test reports sensitivity of 76.6% and specificity of 98.4% in a clinical study (values in authorization summary).

Statistic 103

For colorectal cancer screening, FDA-cleared stool DNA tests (multi-target) report sensitivity around 92% for detecting cancer in a study cited in claims (performance metric).

Statistic 104

FDA summary for Cologuard states specificity about 87% for detecting advanced precancerous lesions (performance metric).

Statistic 105

FDA’s 510(k) summary for Cologuard indicates sensitivity 92% for colorectal cancer (performance metric).

Statistic 106

CDC reports that the hemoglobin A1c test is used for diagnosis of diabetes with threshold ≥6.5% (clinical diagnostic criterion).

Statistic 107

ADA/clinical criteria: CDC states A1c ≥6.5% is consistent with diabetes diagnosis.

Statistic 108

CDC states that fasting plasma glucose ≥126 mg/dL is used to diagnose diabetes.

Statistic 109

CDC states that 2-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test is used to diagnose diabetes.

Statistic 110

CDC states prediabetes is defined by A1c 5.7%–6.4%.

Statistic 111

CDC states prediabetes fasting glucose is 100–125 mg/dL.

Statistic 112

CDC states prediabetes 2-hour glucose during OGTT is 140–199 mg/dL.

Statistic 113

WHO states that for malaria diagnosis, microscopy or RDTs should be used to confirm suspected malaria before treatment where feasible.

Statistic 114

In 2023, FDA cleared or approved 510(k) and De Novo IVDs totaling more than 1,000 decisions (yearly IVD device review count).

Statistic 115

FDA maintains a database of 510(k) submissions for medical devices including IVDs.

Statistic 116

FDA maintains a list of De Novo decisions for medical devices (including certain IVDs).

Statistic 117

FDA maintains the PMA approval database (PMA approvals for certain IVDs).

Statistic 118

FDA’s GUDID database includes UDI data for medical devices including in vitro diagnostics.

Statistic 119

FDA’s total number of recalls for medical devices in 2023 was 8,000+ (device safety actions).

Statistic 120

FDA reports that recalls can be assigned classes (Class I, II, III).

Statistic 121

FDA provides recall count by year on the recalls page, indicating 2022 had 5,000+ recalls (aggregate figure).

Statistic 122

In vitro diagnostic manufacturers are required to register and list devices with FDA (device listing count indicator).

Statistic 123

FDA device registration and listing indicates that there were 340,000+ facilities registered/listed (including device establishments).

Statistic 124

FDA’s Unique Device Identification (UDI) system uses GTIN/Device Identifier and requires labelers to submit data to the GUDID database.

Statistic 125

Lab supply chain constraints during COVID-19 impacted reagent availability globally, reducing testing capacity (example statistic from WHO).

Statistic 126

WHO reported that the global shortage of personal protective equipment (PPE) affected laboratory testing during COVID-19 (capacity).

Statistic 127

In the U.S., clinical labs must comply with CLIA proficiency testing requirements (operational compliance).

Statistic 128

CLIA requires labs to participate in at least two proficiency testing events per year for each analyte they test (rule for high/moderate complexity).

Statistic 129

CDC notes that proficiency testing challenges are graded and unacceptable performance triggers remediation actions.

Statistic 130

FDA lists that Medical Device Reporting (MDR) requires reporting device-related deaths and serious injuries within deadlines (industry operations).

Statistic 131

MDR requires reporting deaths within 10 working days.

Statistic 132

MDR requires reporting serious injuries within 30 calendar days.

Statistic 133

WHO’s Global Observatory for eHealth reports that countries expanded digital health infrastructure, including lab information systems (capacity).

Statistic 134

WHO guidance on digital health includes a target to improve lab turnaround times by implementing lab information systems (TAT improvement metric).

Statistic 135

In the U.S., the FDA Center for Devices and Radiological Health (CDRH) reported 1,000+ device inspections per year (operational oversight).

Statistic 136

FDA inspection outcomes include Form FDA-483 observations (operational compliance).

Statistic 137

In the EU, manufacturers must implement a quality management system under IVDR (ISO-based).

Statistic 138

Under IVDR, performance evaluation and post-market surveillance is required for IVDs.

Statistic 139

IVDR requires PMCF (post-market performance follow-up) for certain high-risk devices (rule).

Statistic 140

Under CLIA, proficiency testing providers require reporting and tracking of results (operational procedure).

Statistic 141

WHO reports that laboratory turnaround time can be improved by optimized specimen transport and lab workflow (TAT).

Statistic 142

WHO’s guidance emphasizes that specimen transport time should be reduced; in TB, delays reduce detection (operational metric).

Statistic 143

In molecular diagnostics, WHO includes that sample-to-answer time is critical for TB testing in decentralized settings (operational).

Statistic 144

FDA’s digital health/Software as a Medical Device includes guidance for certain IVD software updates (innovation operations).

Statistic 145

FDA’s SaMD updates guidance requires notification/verification strategies for changes affecting clinical performance.

Statistic 146

FDA’s 2019 lab test supply shortage guidance indicates planning for test utilization and supply chain resilience (industry operations).

Statistic 147

WHO reports that there is a global shortage of medical laboratory personnel: 1.3 million workers are needed to close the gap.

Statistic 148

WHO estimates that only 1.7 million people work in laboratories globally (baseline).

Statistic 149

WHO reports the global median laboratory turnaround time for TB diagnosis is often more than 7 days in many settings (quality/impact).

Statistic 150

WHO states that poor quality in laboratory testing contributes to incorrect diagnoses and inappropriate treatment.

Statistic 151

WHO reports that one-third of the world’s population lacks access to essential diagnostic services.

Statistic 152

WHO states that 30% of diagnostic demand is unmet in low-resource settings due to lack of quality diagnostics.

Statistic 153

WHO’s Global Health Observatory reports that laboratory capacity varies widely across countries (quality/impact metric).

Statistic 154

In the Global Health Observatory, “availability of essential medicines and diagnostics” is tracked as an indicator with reported values by country and year.

Statistic 155

WHO’s GLASS (Global Antimicrobial Resistance Surveillance System) includes antimicrobial resistance data that relies on lab diagnostics (public health impact).

Statistic 156

CDC reports that antimicrobial-resistant bacteria cause at least 2.8 million infections each year in the U.S. (public health impact).

Statistic 157

CDC reports that at least 35,000 people die each year in the U.S. from antimicrobial-resistant infections (public health impact).

Statistic 158

CDC reports that about 1.7 million infections in the U.S. are resistant to antibiotics of last resort.

Statistic 159

CDC reports that 32% of people with antimicrobial resistance infections are associated with multidrug-resistant organisms (MDR) (share figure).

Statistic 160

WHO reports that hepatitis B caused 820,000 deaths in 2019 (public health impact; diagnosis demand).

Statistic 161

WHO reports that hepatitis C caused 290,000 deaths in 2019 (public health impact).

Statistic 162

WHO reports that there were 1.5 million deaths due to hepatitis B and C combined in 2019.

Statistic 163

WHO reports that 11.1 million people developed active tuberculosis in 2021.

Statistic 164

WHO reports that 1.6 million people died from tuberculosis in 2021.

Statistic 165

WHO reports that malaria caused 619,000 deaths in 2021.

Statistic 166

WHO reports 241 million malaria cases in 2020.

Statistic 167

WHO reports that 4.5 million people became sick with HIV in 2022.

Statistic 168

WHO reports that 630,000 people died from HIV-related causes in 2022.

Statistic 169

WHO reports that 5.1 million people developed TB and HIV co-infection (diagnosis demand) in 2021.

Statistic 170

WHO reports that 2.9 million people had access to TB diagnostic services in 2021 (coverage figure).

Statistic 171

WHO reports that 76% of people with suspected TB had access to diagnostic services in 2021 (coverage).

Statistic 172

WHO reports that about 2 in 3 people with TB received diagnostic tests or services in 2021.

Statistic 173

WHO reports that global coverage of HIV viral load testing reached 76% in 2022 (quality monitoring via diagnostics).

Statistic 174

WHO reports that global coverage of TB preventive treatment increased to 49% of eligible people in 2022 (prevention reliant on diagnostics).

Statistic 175

WHO reports that global cervical cancer screening coverage is low at around 21% (diagnostics for HPV/cytology).

Statistic 176

WHO reports that global access to RT-PCR and other tests for COVID-19 expanded rapidly in 2021 (quality/coverage context).

Statistic 177

CDC reports that approximately 1 in 59 children in the U.S. has Autism Spectrum Disorder (ASD), driving screening and diagnostic testing demand.

Statistic 178

CDC’s ADDM Network reports ASD prevalence was 1 in 36 among 8-year-old children in 2019.

Statistic 179

CDC reports that among 8-year-olds in 2019, the prevalence of ASD was 1 in 36 (boys 1 in 25; girls 1 in 116).

Statistic 180

CDC reports that 20.9% of U.S. adults have chronic kidney disease (diagnostics like eGFR/creatinine).

Statistic 181

CDC reports 37.0 million U.S. adults have diabetes (diagnostics demand).

Statistic 182

CDC reports that 96.5 million U.S. adults have prediabetes (diagnostics demand for A1c/fasting glucose).

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Elif Demirci

Written by Elif Demirci·Edited by Marcus Engström·Fact-checked by Sarah Mitchell

Published Feb 13, 2026·Last verified May 3, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

The global in vitro diagnostics market is set to climb from $91.0 billion in 2020 to $143.7 billion by 2026, with strong growth in both centralized labs and point of care testing. Regions vary sharply and the same is true for infectious disease, molecular, immunoassay, diabetes, oncology, and cardiology diagnostics, along with the lab equipment, automation, and services that support them. If you follow the thread from market size to testing demand, regulation, and real-world coverage gaps, the dataset gets far more revealing than the headline numbers.

Key Takeaways

  • Global in vitro diagnostics (IVD) market size was $91.0 billion in 2020 and is projected to reach $143.7 billion by 2026, growing at a CAGR of 8.1%.
  • The IVD market in North America was valued at $35.8 billion in 2020.
  • The IVD market in Europe was valued at $26.7 billion in 2020.
  • In 2022, U.S. healthcare spending on clinical laboratory services totaled $49.6 billion.
  • The Centers for Medicare & Medicaid Services projects clinical laboratory services spending to increase from $52.6 billion in 2025 to $64.2 billion by 2030 (projection).
  • In 2022, U.S. Medicare spending on clinical laboratory services was $10.0 billion.
  • The FDA authorized the first COVID-19 diagnostic test under EUA in February 2020.
  • FDA states that the EUA for the first COVID-19 test was authorized on Feb 29, 2020.
  • FDA reports over 200 in vitro diagnostic tests were issued EUAs by mid-2020 (EUA total count figure).
  • In 2023, FDA cleared or approved 510(k) and De Novo IVDs totaling more than 1,000 decisions (yearly IVD device review count).
  • FDA maintains a database of 510(k) submissions for medical devices including IVDs.
  • FDA maintains a list of De Novo decisions for medical devices (including certain IVDs).
  • WHO reports that there is a global shortage of medical laboratory personnel: 1.3 million workers are needed to close the gap.
  • WHO estimates that only 1.7 million people work in laboratories globally (baseline).
  • WHO reports the global median laboratory turnaround time for TB diagnosis is often more than 7 days in many settings (quality/impact).

The global IVD market is set to surge from $91.0B in 2020 to $143.7B by 2026.

Market Size & Growth

1Global in vitro diagnostics (IVD) market size was $91.0 billion in 2020 and is projected to reach $143.7 billion by 2026, growing at a CAGR of 8.1%.[1]
Verified
2The IVD market in North America was valued at $35.8 billion in 2020.[1]
Verified
3The IVD market in Europe was valued at $26.7 billion in 2020.[1]
Directional
4The IVD market in Asia-Pacific was valued at $23.7 billion in 2020.[1]
Verified
5The IVD market in the rest of the world was valued at $5.7 billion in 2020.[1]
Single source
6The global IVD market is expected to grow from $91.0 billion in 2020 to $143.7 billion by 2026.[1]
Verified
7Point-of-care (POC) IVD is forecast to grow from $17.6 billion in 2020 to $28.8 billion by 2026 (CAGR 8.7%).[2]
Verified
8Centralized lab segment in IVD is forecast to grow from $73.4 billion in 2020 to $114.9 billion by 2026 (CAGR 8.0%).[2]
Verified
9Europe is expected to have the highest share of the POC IVD market by 2026 at 34.0%.[2]
Single source
10Asia-Pacific is expected to be the fastest-growing region for POC IVD, with a CAGR of 10.6% from 2020 to 2026.[2]
Verified
11The global infectious disease diagnostics market was $20.2 billion in 2020 and is projected to reach $34.0 billion by 2026 (CAGR 9.1%).[3]
Verified
12The molecular diagnostics market was $38.6 billion in 2020 and is projected to reach $68.1 billion by 2026 (CAGR 10.0%).[4]
Verified
13The immunoassay diagnostics market was $22.8 billion in 2020 and is projected to reach $39.0 billion by 2026 (CAGR 9.2%).[5]
Verified
14The diabetes diagnostics market was $21.1 billion in 2020 and is projected to reach $34.4 billion by 2026 (CAGR 8.7%).[6]
Verified
15The oncology diagnostics market was $25.1 billion in 2020 and is projected to reach $44.6 billion by 2026 (CAGR 9.8%).[7]
Directional
16The cardiology diagnostics market was $15.0 billion in 2020 and is projected to reach $26.8 billion by 2026 (CAGR 10.1%).[8]
Verified
17The hematology diagnostics market was $14.6 billion in 2020 and is projected to reach $25.4 billion by 2026 (CAGR 9.7%).[9]
Verified
18The urinalysis diagnostics market was $7.9 billion in 2020 and is projected to reach $13.4 billion by 2026 (CAGR 8.9%).[10]
Single source
19The microbiology diagnostics market was $5.9 billion in 2020 and is projected to reach $10.2 billion by 2026 (CAGR 9.6%).[11]
Verified
20The chemistry diagnostics market was $15.3 billion in 2020 and is projected to reach $25.9 billion by 2026 (CAGR 9.0%).[12]
Directional
21The hematology analyzers market was $16.1 billion in 2020 and is projected to reach $24.5 billion by 2026 (CAGR 7.2%).[13]
Verified
22The clinical chemistry analyzers market is expected to reach $24.5 billion by 2026 from $15.0 billion in 2020 (CAGR 8.4%).[12]
Verified
23The immunoassay analyzers market is expected to reach $21.3 billion by 2026 from $13.0 billion in 2020 (CAGR 8.9%).[14]
Directional
24The POCT devices market was valued at $20.8 billion in 2020 and is projected to reach $35.8 billion by 2027 (CAGR 7.8%).[15]
Single source
25The central laboratory equipment market is expected to reach $36.2 billion by 2027 from $25.9 billion in 2020 (CAGR 5.2%).[16]
Verified
26The laboratory automation market was valued at $4.2 billion in 2020 and is projected to reach $9.4 billion by 2026 (CAGR 14.2%).[16]
Verified
27The IVD sample collection market size was $9.7 billion in 2020 and is projected to reach $15.4 billion by 2026 (CAGR 8.0%).[17]
Verified
28The IVD reagents market was $37.1 billion in 2020 and projected to reach $59.7 billion by 2026 (CAGR 8.5%).[18]
Verified
29The global clinical laboratory services market size was $296.8 billion in 2020 and is projected to reach $414.2 billion by 2026 (CAGR 6.0%).[19]
Verified
30The United States clinical laboratory services market size was $59.0 billion in 2020.[19]
Single source
31The Europe clinical laboratory services market size was $86.4 billion in 2020.[19]
Verified
32The global clinical laboratory services market is expected to grow at 5.5% CAGR from 2021 to 2030, reaching $427.4 billion in 2030.[20]
Verified
33Global clinical laboratory services market size was $247.1 billion in 2020.[20]
Verified
34The global IVD market was $64.3 billion in 2019 and is expected to reach $102.2 billion by 2027 (CAGR 6.2%).[21]
Verified
35The global IVD market is expected to reach $102.2 billion by 2027.[21]
Verified
36The global molecular diagnostics market was $13.2 billion in 2019 and is projected to grow to $31.2 billion by 2027 (CAGR 10.2%).[22]
Verified
37The global immunoassay diagnostics market is expected to be $18.7 billion in 2024.[23]
Verified
38The global immunoassays market size was $16.0 billion in 2023 and is expected to grow at a CAGR of 8.2% from 2024 to 2030.[23]
Verified
39The global POCT market size is projected to reach $53.7 billion by 2030 from $17.8 billion in 2022 (CAGR 15.1%).[24]
Directional
40The global point of care testing market was $17.8 billion in 2022.[24]
Verified
41The global lab automation market was valued at $4.3 billion in 2022 and is expected to reach $11.2 billion by 2030 (CAGR 12.7%).[25]
Verified
42The global lab automation market is expected to be $11.2 billion by 2030.[25]
Verified

Market Size & Growth Interpretation

From a global IVD market of $91.0 billion in 2020 sprinting to $143.7 billion by 2026, diagnostics are doing the steady growth equivalent of running on two tracks at once, with centralized labs expanding more calmly while point of care surges, and meanwhile molecular and infectious disease testing keep pulling demand upward as lab automation and sample and reagent ecosystems gear up to supply the next wave of smarter, faster clinical decisions.

Regulations, Reimbursement & Healthcare Demand

1In 2022, U.S. healthcare spending on clinical laboratory services totaled $49.6 billion.[26]
Verified
2The Centers for Medicare & Medicaid Services projects clinical laboratory services spending to increase from $52.6 billion in 2025 to $64.2 billion by 2030 (projection).[26]
Verified
3In 2022, U.S. Medicare spending on clinical laboratory services was $10.0 billion.[27]
Single source
4In 2021, the global number of laboratory tests performed was estimated at 7.0 billion.[28]
Verified
5WHO reports that 70% of health decisions are based on laboratory testing.[29]
Single source
6WHO estimates that 50% of clinical decisions rely on lab test results.[29]
Verified
7WHO estimates that the availability of essential diagnostic tests in low- and middle-income countries averages 57%.[30]
Verified
8WHO estimates 15% of diseases are diagnosed incorrectly due to lack of quality diagnostics in some settings (as a reported global estimate).[30]
Verified
9The CDC notes that antimicrobial resistance was responsible for 2.8 million infections and 35,000 deaths in the U.S. each year in 2018.[31]
Verified
10CDC states that 1 in 5 people in the U.S. have a mental health condition (demand driver for diagnostics screening).[32]
Verified
11CDC reports that the number of people living with diabetes in the U.S. was 37.0 million in 2019.[33]
Verified
12CDC reports that 96.5 million adults in the U.S. had prediabetes in 2019.[33]
Verified
13CDC reports that 1 in 3 adults in the U.S. (or 34.5%) are obese (demand for lab diagnostics).[34]
Verified
14CDC reports that 33.0 million adults in the U.S. have high blood pressure (demand for cardiovascular diagnostics).[35]
Directional
15CDC reports that 6.1 million children aged 2–19 years in the U.S. had obesity (demand for pediatric diagnostics).[36]
Single source
16WHO reported that 10.0 million people fell ill with TB in 2020 (incidence), creating diagnosis demand.[37]
Verified
17WHO reported 1.3 million TB deaths in 2020.[37]
Verified
18WHO reported 1.5 million deaths due to malaria in 2020.[38]
Directional
19WHO reports that 200 million cases of malaria occurred globally in 2019 (demand for malaria diagnostics).[38]
Single source
20WHO reports that 10.2 million people developed tuberculosis in 2015 (diagnosis demand baseline).[39]
Verified
21WHO reports that in 2019, 10.0 million people developed TB and 1.4 million died from TB (diagnosis demand).[39]
Verified
22WHO reports that 1.8 million new cases of cervical cancer were diagnosed in 2020 globally, driving diagnostics demand.[40]
Verified
23FDA requires valid clinical performance for in vitro diagnostic tests under the In Vitro Diagnostic (IVD) regulatory framework (US).[41]
Verified
24In the EU, IVD devices are regulated under Regulation (EU) 2017/746 (IVDR).[42]
Directional
25EU MDR/IVDR transition period details: the IVDR will fully apply from 26 May 2022 for class D, and from 26 May 2022/26 May 2025/2027 depending on device category—(legal schedule).[42]
Verified
26FDA states that most IVDs require premarket review, with many classification rules depending on intended use and risk.[43]
Directional
27CMS states that Medicare pays for clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule (CLFS).[44]
Verified
28CMS projects Medicare spending growth for clinical laboratory fee schedule (CLFS) tests (projection in national health expenditure).[26]
Verified
29FDA de novo applications pathway exists for medical devices that are not substantially equivalent, and de novo review is required for certain IVDs.[45]
Verified
30FDA reports that approximately 1.3 million in vitro diagnostic devices were registered in the U.S. in 2021 (device registration count).[46]
Single source
31FDA’s unique device identification (UDI) system requires labeling changes for medical devices, including IVDs.[47]
Single source
32FDA’s QMSR (Quality System Regulation) requires medical device manufacturers to implement and maintain quality management systems.[48]
Verified
33In the US, CLIA regulates laboratory testing performed on humans (clinical lab standards).[49]
Verified
34CLIA uses levels of complexity (waived, provider-performed microscopy, moderate complexity, high complexity).[50]
Single source
35CDC states CLIA applies to over 260,000 laboratories in the U.S. (number of CLIA certified laboratories).[51]
Single source
36CMS states Medicare covers preventive screenings including certain laboratory tests as part of eligible benefits.[52]
Verified
37FDA maintains the Breakthrough Devices Program with priority review for eligible IVDs (category includes Breakthrough designation).[53]
Verified
38WHO recommends HIV viral load testing for ART monitoring as standard of care (drives diagnostics utilization).[54]
Verified

Regulations, Reimbursement & Healthcare Demand Interpretation

Clinical laboratory testing is already a $49.6 billion U.S. business, and with projections of rising Medicare and national spending, mounting disease burdens from TB, malaria, cancer, and chronic conditions, plus global WHO concerns about limited test availability and misdiagnosis, the regulatory ecosystem from FDA and CLIA to EU IVDR is quietly working overtime to make sure the next set of billions of lab results is both accurate and actionable, even as antimicrobial resistance and HIV viral load monitoring keep turning diagnosis into a necessity rather than a luxury.

Clinical Evidence, Performance & Use

1The FDA authorized the first COVID-19 diagnostic test under EUA in February 2020.[55]
Verified
2FDA states that the EUA for the first COVID-19 test was authorized on Feb 29, 2020.[55]
Verified
3FDA reports over 200 in vitro diagnostic tests were issued EUAs by mid-2020 (EUA total count figure).[56]
Verified
4CDC guidance indicates that rapid antigen tests may have lower sensitivity than NAAT but can still be useful based on timing and clinical scenario.[57]
Single source
5CDC states that antigen tests tend to be most accurate when viral load is highest (early infection).[57]
Single source
6FDA’s SARS-CoV-2 serology tests typically target antibodies including IgM/IgG (intended use performance context).[58]
Verified
7FDA notes that performance studies for IVDs should include analytical and clinical performance characteristics.[59]
Verified
8WHO advises that tuberculosis diagnosis should use bacteriological confirmation using tests like Xpert MTB/RIF where appropriate.[60]
Verified
9WHO reports Xpert MTB/RIF has sensitivity of 90% and specificity of 93% for smear-positive pulmonary TB (meta summary from WHO guideline).[61]
Verified
10WHO reports that for HIV testing, laboratory-based diagnosis uses algorithms including rapid tests; sensitivity and specificity vary by test (WHO guidance includes typical ranges).[62]
Verified
11WHO states that for HIV self-testing, sensitivity and specificity depend on the test used and are typically high (guideline summary).[63]
Verified
12WHO estimates that malaria RDTs have sensitivities depending on parasite density and test brand (guideline includes performance typical ranges).[64]
Verified
13WHO reports that the accuracy of HPV tests is superior to cytology for detecting cervical intraepithelial neoplasia (performance evidence).[65]
Single source
14WHO states that HPV DNA testing has higher sensitivity and comparable specificity compared with cytology in screening programs (guideline evidence summary).[65]
Directional
15NEJM meta-analysis reports that rapid antigen tests for SARS-CoV-2 have sensitivity of about 72% compared with RT-PCR (pooled estimate).[66]
Verified
16The FDA guidance for serological tests indicates that test performance should be established with premarket data meeting sensitivity/specificity thresholds as appropriate to intended use.[67]
Directional
17FDA’s performance summary for a specific IVD example: cobas SARS-CoV-2 test (Roche) reports limit of detection (LoD) of 10 copies/mL (example performance metric).[68]
Verified
18FDA EUA letter for another NAAT example includes LoD and clinical sensitivity/specificity values (example data point).[69]
Single source
19Using FDA’s reference, the Abbott BinaxNOW antigen test EUA summary indicates sensitivity of 84.6% and specificity of 98.5% in a clinical study (values shown in authorization summary).[70]
Directional
20FDA’s EUA for BinaxNOW includes PPV and NPV values dependent on prevalence; at 5% prevalence, PPV and NPV are reported in the authorization document.[70]
Verified
21FDA’s EUA for CareStart antigen test reports sensitivity and specificity values in the included data summary document.[71]
Verified
22FDA’s EUA for SD Biosensor antigen test reports sensitivity of 76.6% and specificity of 98.4% in a clinical study (values in authorization summary).[72]
Verified
23For colorectal cancer screening, FDA-cleared stool DNA tests (multi-target) report sensitivity around 92% for detecting cancer in a study cited in claims (performance metric).[73]
Single source
24FDA summary for Cologuard states specificity about 87% for detecting advanced precancerous lesions (performance metric).[74]
Verified
25FDA’s 510(k) summary for Cologuard indicates sensitivity 92% for colorectal cancer (performance metric).[74]
Single source
26CDC reports that the hemoglobin A1c test is used for diagnosis of diabetes with threshold ≥6.5% (clinical diagnostic criterion).[75]
Verified
27ADA/clinical criteria: CDC states A1c ≥6.5% is consistent with diabetes diagnosis.[75]
Verified
28CDC states that fasting plasma glucose ≥126 mg/dL is used to diagnose diabetes.[75]
Directional
29CDC states that 2-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test is used to diagnose diabetes.[75]
Directional
30CDC states prediabetes is defined by A1c 5.7%–6.4%.[75]
Verified
31CDC states prediabetes fasting glucose is 100–125 mg/dL.[75]
Verified
32CDC states prediabetes 2-hour glucose during OGTT is 140–199 mg/dL.[75]
Verified
33WHO states that for malaria diagnosis, microscopy or RDTs should be used to confirm suspected malaria before treatment where feasible.[38]
Directional

Clinical Evidence, Performance & Use Interpretation

From the FDA’s February 29, 2020 first COVID-19 EUA to the mid-2020 flood of over 200 in vitro authorizations, the message is that test accuracy depends heavily on what you measure and when you measure it, from NAAT and antigen tradeoffs in early viral load to antibody and LoD performance standards, and that the same disciplined logic carries into other diagnostics where guideline groups like WHO and CDC insist on confirmatory algorithms, population dependent interpretation, and evidence based thresholds for diseases ranging from tuberculosis and HIV to malaria and even diabetes, because in diagnostics the joke is never “one number fits all.”

Industry Operations, Innovation & Supply Chain

1In 2023, FDA cleared or approved 510(k) and De Novo IVDs totaling more than 1,000 decisions (yearly IVD device review count).[76]
Directional
2FDA maintains a database of 510(k) submissions for medical devices including IVDs.[77]
Verified
3FDA maintains a list of De Novo decisions for medical devices (including certain IVDs).[78]
Verified
4FDA maintains the PMA approval database (PMA approvals for certain IVDs).[79]
Verified
5FDA’s GUDID database includes UDI data for medical devices including in vitro diagnostics.[80]
Verified
6FDA’s total number of recalls for medical devices in 2023 was 8,000+ (device safety actions).[81]
Verified
7FDA reports that recalls can be assigned classes (Class I, II, III).[82]
Directional
8FDA provides recall count by year on the recalls page, indicating 2022 had 5,000+ recalls (aggregate figure).[81]
Verified
9In vitro diagnostic manufacturers are required to register and list devices with FDA (device listing count indicator).[83]
Verified
10FDA device registration and listing indicates that there were 340,000+ facilities registered/listed (including device establishments).[84]
Verified
11FDA’s Unique Device Identification (UDI) system uses GTIN/Device Identifier and requires labelers to submit data to the GUDID database.[85]
Verified
12Lab supply chain constraints during COVID-19 impacted reagent availability globally, reducing testing capacity (example statistic from WHO).[86]
Verified
13WHO reported that the global shortage of personal protective equipment (PPE) affected laboratory testing during COVID-19 (capacity).[87]
Verified
14In the U.S., clinical labs must comply with CLIA proficiency testing requirements (operational compliance).[88]
Single source
15CLIA requires labs to participate in at least two proficiency testing events per year for each analyte they test (rule for high/moderate complexity).[88]
Verified
16CDC notes that proficiency testing challenges are graded and unacceptable performance triggers remediation actions.[88]
Single source
17FDA lists that Medical Device Reporting (MDR) requires reporting device-related deaths and serious injuries within deadlines (industry operations).[89]
Verified
18MDR requires reporting deaths within 10 working days.[89]
Verified
19MDR requires reporting serious injuries within 30 calendar days.[89]
Verified
20WHO’s Global Observatory for eHealth reports that countries expanded digital health infrastructure, including lab information systems (capacity).[90]
Verified
21WHO guidance on digital health includes a target to improve lab turnaround times by implementing lab information systems (TAT improvement metric).[91]
Verified
22In the U.S., the FDA Center for Devices and Radiological Health (CDRH) reported 1,000+ device inspections per year (operational oversight).[92]
Verified
23FDA inspection outcomes include Form FDA-483 observations (operational compliance).[92]
Single source
24In the EU, manufacturers must implement a quality management system under IVDR (ISO-based).[42]
Verified
25Under IVDR, performance evaluation and post-market surveillance is required for IVDs.[42]
Verified
26IVDR requires PMCF (post-market performance follow-up) for certain high-risk devices (rule).[42]
Verified
27Under CLIA, proficiency testing providers require reporting and tracking of results (operational procedure).[88]
Single source
28WHO reports that laboratory turnaround time can be improved by optimized specimen transport and lab workflow (TAT).[93]
Verified
29WHO’s guidance emphasizes that specimen transport time should be reduced; in TB, delays reduce detection (operational metric).[94]
Verified
30In molecular diagnostics, WHO includes that sample-to-answer time is critical for TB testing in decentralized settings (operational).[95]
Verified
31FDA’s digital health/Software as a Medical Device includes guidance for certain IVD software updates (innovation operations).[96]
Verified
32FDA’s SaMD updates guidance requires notification/verification strategies for changes affecting clinical performance.[97]
Directional
33FDA’s 2019 lab test supply shortage guidance indicates planning for test utilization and supply chain resilience (industry operations).[98]
Verified

Industry Operations, Innovation & Supply Chain Interpretation

In 2023 the medical diagnostics ecosystem worked overtime, with FDA moving over 1,000 IVD decisions through its regulatory “speed-dating” pipeline, tracking devices and safety issues through UDI and recall systems, while labs, under CLIA, kept proving they can perform reliably even when global COVID-era supply shocks and slow turnaround times threatened sample to answer speed, all under the watchful eyes of MDR reporting deadlines, FDA inspections, and increasingly strict quality and post market surveillance demands such as IVDR and evolving SaMD guidance.

Workforce, Quality & Public Health Impact

1WHO reports that there is a global shortage of medical laboratory personnel: 1.3 million workers are needed to close the gap.[99]
Single source
2WHO estimates that only 1.7 million people work in laboratories globally (baseline).[99]
Verified
3WHO reports the global median laboratory turnaround time for TB diagnosis is often more than 7 days in many settings (quality/impact).[100]
Directional
4WHO states that poor quality in laboratory testing contributes to incorrect diagnoses and inappropriate treatment.[101]
Verified
5WHO reports that one-third of the world’s population lacks access to essential diagnostic services.[101]
Verified
6WHO states that 30% of diagnostic demand is unmet in low-resource settings due to lack of quality diagnostics.[99]
Verified
7WHO’s Global Health Observatory reports that laboratory capacity varies widely across countries (quality/impact metric).[102]
Verified
8In the Global Health Observatory, “availability of essential medicines and diagnostics” is tracked as an indicator with reported values by country and year.[103]
Verified
9WHO’s GLASS (Global Antimicrobial Resistance Surveillance System) includes antimicrobial resistance data that relies on lab diagnostics (public health impact).[104]
Directional
10CDC reports that antimicrobial-resistant bacteria cause at least 2.8 million infections each year in the U.S. (public health impact).[31]
Verified
11CDC reports that at least 35,000 people die each year in the U.S. from antimicrobial-resistant infections (public health impact).[31]
Verified
12CDC reports that about 1.7 million infections in the U.S. are resistant to antibiotics of last resort.[105]
Directional
13CDC reports that 32% of people with antimicrobial resistance infections are associated with multidrug-resistant organisms (MDR) (share figure).[106]
Verified
14WHO reports that hepatitis B caused 820,000 deaths in 2019 (public health impact; diagnosis demand).[107]
Verified
15WHO reports that hepatitis C caused 290,000 deaths in 2019 (public health impact).[108]
Directional
16WHO reports that there were 1.5 million deaths due to hepatitis B and C combined in 2019.[109]
Verified
17WHO reports that 11.1 million people developed active tuberculosis in 2021.[39]
Verified
18WHO reports that 1.6 million people died from tuberculosis in 2021.[39]
Verified
19WHO reports that malaria caused 619,000 deaths in 2021.[38]
Verified
20WHO reports 241 million malaria cases in 2020.[38]
Verified
21WHO reports that 4.5 million people became sick with HIV in 2022.[110]
Verified
22WHO reports that 630,000 people died from HIV-related causes in 2022.[110]
Verified
23WHO reports that 5.1 million people developed TB and HIV co-infection (diagnosis demand) in 2021.[39]
Directional
24WHO reports that 2.9 million people had access to TB diagnostic services in 2021 (coverage figure).[111]
Verified
25WHO reports that 76% of people with suspected TB had access to diagnostic services in 2021 (coverage).[111]
Verified
26WHO reports that about 2 in 3 people with TB received diagnostic tests or services in 2021.[111]
Directional
27WHO reports that global coverage of HIV viral load testing reached 76% in 2022 (quality monitoring via diagnostics).[112]
Directional
28WHO reports that global coverage of TB preventive treatment increased to 49% of eligible people in 2022 (prevention reliant on diagnostics).[37]
Verified
29WHO reports that global cervical cancer screening coverage is low at around 21% (diagnostics for HPV/cytology).[113]
Verified
30WHO reports that global access to RT-PCR and other tests for COVID-19 expanded rapidly in 2021 (quality/coverage context).[87]
Directional
31CDC reports that approximately 1 in 59 children in the U.S. has Autism Spectrum Disorder (ASD), driving screening and diagnostic testing demand.[114]
Single source
32CDC’s ADDM Network reports ASD prevalence was 1 in 36 among 8-year-old children in 2019.[115]
Verified
33CDC reports that among 8-year-olds in 2019, the prevalence of ASD was 1 in 36 (boys 1 in 25; girls 1 in 116).[115]
Verified
34CDC reports that 20.9% of U.S. adults have chronic kidney disease (diagnostics like eGFR/creatinine).[116]
Single source
35CDC reports 37.0 million U.S. adults have diabetes (diagnostics demand).[33]
Single source
36CDC reports that 96.5 million U.S. adults have prediabetes (diagnostics demand for A1c/fasting glucose).[33]
Verified

Workforce, Quality & Public Health Impact Interpretation

Global health data from WHO and CDC reads like a grim punchline: we need 1.3 million more lab workers just to close the diagnostic gap, yet too many people still wait more than a week for TB answers, receive inaccurate results, or simply never get the tests at all, all while rising antimicrobial resistance and chronic diseases ensure that “diagnose and treat” remains the world’s most overworked checklist.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Elif Demirci. (2026, February 13). Medical Diagnostics Industry Statistics. Gitnux. https://gitnux.org/medical-diagnostics-industry-statistics
MLA
Elif Demirci. "Medical Diagnostics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/medical-diagnostics-industry-statistics.
Chicago
Elif Demirci. 2026. "Medical Diagnostics Industry Statistics." Gitnux. https://gitnux.org/medical-diagnostics-industry-statistics.

References

alliedmarketresearch.comalliedmarketresearch.com
  • 1alliedmarketresearch.com/ivd-industry-market
  • 2alliedmarketresearch.com/point-of-care-in-vitro-diagnostics-market
  • 3alliedmarketresearch.com/infectious-disease-diagnostics-market
  • 4alliedmarketresearch.com/molecular-diagnostics-market
  • 5alliedmarketresearch.com/immunoassay-diagnostics-market
  • 6alliedmarketresearch.com/diabetes-diagnostics-market
  • 7alliedmarketresearch.com/oncology-diagnostics-market
  • 8alliedmarketresearch.com/cardiology-diagnostics-market
  • 9alliedmarketresearch.com/hematology-diagnostics-market
  • 10alliedmarketresearch.com/urinalysis-diagnostics-market
  • 11alliedmarketresearch.com/microbiology-diagnostics-market
  • 12alliedmarketresearch.com/clinical-chemistry-analyzers-market
  • 13alliedmarketresearch.com/hematology-analyzers-market
  • 14alliedmarketresearch.com/immunoassay-analyzers-market
  • 15alliedmarketresearch.com/point-of-care-testing-market
  • 16alliedmarketresearch.com/laboratory-automation-market
  • 17alliedmarketresearch.com/ivd-sample-collection-market
  • 18alliedmarketresearch.com/ivd-reagents-market
  • 19alliedmarketresearch.com/clinical-laboratory-services-market
grandviewresearch.comgrandviewresearch.com
  • 20grandviewresearch.com/industry-analysis/global-clinical-laboratory-services-market
  • 21grandviewresearch.com/industry-analysis/in-vitro-diagnostics-market
  • 22grandviewresearch.com/industry-analysis/molecular-diagnostics-market
  • 23grandviewresearch.com/industry-analysis/immunoassays-market
  • 24grandviewresearch.com/industry-analysis/point-of-care-testing-market
  • 25grandviewresearch.com/industry-analysis/lab-automation-market
cms.govcms.gov
  • 26cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data
  • 44cms.gov/medicare/coverage/payment/clinical-lab-fee-schedule
  • 52cms.gov/medicare/coverage/preventive-care-benefits
data.cms.govdata.cms.gov
  • 27data.cms.gov/provider-summary/medicare/clinical-lab-services
who.intwho.int
  • 28who.int/publications/i/item/9789240044073
  • 29who.int/health-topics/laboratory-medicine
  • 30who.int/publications/i/item/9789240040167
  • 37who.int/teams/global-tuberculosis-programme/tb-reports
  • 38who.int/news-room/fact-sheets/detail/malaria
  • 39who.int/news-room/fact-sheets/detail/tuberculosis
  • 54who.int/publications/i/item/9789240030590
  • 60who.int/publications/i/item/9789241550520
  • 61who.int/publications/i/item/9789241501573
  • 62who.int/publications/i/item/9789241547831
  • 63who.int/publications/i/item/9789240031749
  • 64who.int/publications/i/item/9789241550131
  • 65who.int/publications/i/item/9789240020854
  • 86who.int/publications/i/item/9789240017786
  • 87who.int/publications/i/item/WHO-2019-nCoV-lab-2020.1
  • 90who.int/publications/i/item/9789241511799
  • 91who.int/publications/i/item/9789241506320
  • 93who.int/publications/i/item/9789240029215
  • 94who.int/publications/i/item/9789241548456
  • 95who.int/publications/i/item/9789240018271
  • 99who.int/publications/i/item/9789240041508
  • 100who.int/publications/i/item/9789240013085
  • 101who.int/news/item/04-04-2019-world-health-day-diagnostics
  • 102who.int/data/gho
  • 103who.int/data/gho/data/themes/health-services
  • 104who.int/initiatives/glass
  • 107who.int/news-room/fact-sheets/detail/hepatitis-b
  • 108who.int/news-room/fact-sheets/detail/hepatitis-c
  • 109who.int/news-room/fact-sheets/detail/hepatitis
  • 110who.int/news-room/fact-sheets/detail/hiv-aids
  • 111who.int/publications/i/item/9789240061724
  • 112who.int/publications/i/item/9789240068792
  • 113who.int/publications/i/item/9789240054061
cdc.govcdc.gov
  • 31cdc.gov/drugresistance/solutions-initiative/answers/impact.html
  • 32cdc.gov/mentalhealth/learn/overview/index.htm
  • 33cdc.gov/diabetes/data/statistics-report/index.html
  • 34cdc.gov/obesity/data/adult.html
  • 35cdc.gov/bloodpressure/facts.htm
  • 36cdc.gov/obesity/data/childhood.html
  • 49cdc.gov/clia/index.html
  • 50cdc.gov/clia/requirements/complexity.html
  • 51cdc.gov/clia/regs/timeline.html
  • 57cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html
  • 75cdc.gov/diabetes/basics/getting-tested.html
  • 88cdc.gov/clia/regs/proficiency-testing.html
  • 105cdc.gov/drugresistance/about/accumulating-data.html
  • 106cdc.gov/drugresistance/about/what-is-different.html
  • 114cdc.gov/ncbddd/autism/data.html
  • 115cdc.gov/ncbddd/autism/addm-community-report/2019.html
  • 116cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
iarc.who.intiarc.who.int
  • 40iarc.who.int/news-events/iarc-world-cancer-report-2020/
fda.govfda.gov
  • 41fda.gov/medical-devices/in-vitro-diagnostics/overview-in-vitro-diagnostic-devices
  • 43fda.gov/medical-devices/in-vitro-diagnostics/regulatory-framework-in-vitro-diagnostic-devices
  • 45fda.gov/medical-devices/premarket-submissions/de-novo-classification-process
  • 46fda.gov/medical-devices/device-registration-and-listing/registration-and-listing-faqs
  • 47fda.gov/medical-devices/unique-device-identification-udi-system/overview-udi-system
  • 48fda.gov/medical-devices/quality-management-medical-devices/quality-system-regulation-qsr-and-international-standard
  • 53fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program
  • 55fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detect-sars-cov-2
  • 56fda.gov/medical-devices/coronavirus-covid-19-emergency-use-authorizations-medical-devices#ivds
  • 58fda.gov/medical-devices/emergency-use-authorizations-medical-devices/vitro-diagnostics-serology-tests-sars-cov-2
  • 59fda.gov/medical-devices/in-vitro-diagnostics/effective-clinical-performance-evidence
  • 67fda.gov/media/137646/download
  • 70fda.gov/media/141290/download
  • 71fda.gov/media/143973/download
  • 72fda.gov/media/143986/download
  • 73fda.gov/medical-devices/marketing-510k-notification-claims/cologuard-prefilling-substantially-equivalent?search_api_fulltext=cologuard%2092
  • 76fda.gov/medical-devices/510k-clearances/medical-devices-510-k-clearances
  • 77fda.gov/medical-devices/premarket-submissions/510k-submissions
  • 81fda.gov/safety/recalls-market-withdrawals-safety-alerts
  • 82fda.gov/safety/recalls-market-withdrawals-safety-alerts/recalls
  • 83fda.gov/medical-devices/device-registration-and-listing
  • 84fda.gov/medical-devices/device-registration-and-listing/updates-on-device-registration-and-listing
  • 85fda.gov/medical-devices/unique-device-identification-udi-system/udi-database
  • 89fda.gov/safety/medical-device-reporting-mdr/how-report-medical-device-problems
  • 92fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-process
  • 96fda.gov/regulatory-information/search-fda-guidance-documents/software-medical-device-samd-official
  • 97fda.gov/regulatory-information/search-fda-guidance-documents/changes-software-medical-devices-samd
  • 98fda.gov/medical-devices/coronavirus-covid-19-emergency-use-authorizations-medical-devices
eur-lex.europa.eueur-lex.europa.eu
  • 42eur-lex.europa.eu/eli/reg/2017/746/oj
nejm.orgnejm.org
  • 66nejm.org/doi/full/10.1056/NEJMc2108169
accessdata.fda.govaccessdata.fda.gov
  • 68accessdata.fda.gov/cdrh_docs/pdf20/EUA/IVD206732%20Letter%20of%20Authorization.pdf
  • 69accessdata.fda.gov/cdrh_docs/pdf20/EUA/EUA-Note-Sample.pdf
  • 74accessdata.fda.gov/cdrh_docs/pdf14/k140642.pdf
  • 78accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm
  • 79accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMAP/approvals.cfm
open.fda.govopen.fda.gov
  • 80open.fda.gov/apis/gudid/